Patent Analytics Research Report

Transcription

1 SANGAMO THERAPEUTICS Patent Analytics Research Report May 2018 CRISPR IP assets Copy for IPStudies Corporate access

2 Executive summary This research report specifically reviews the IP strategy and positioning of IP assets by Sangamo Therapeutics ( Sangamo, NASDAQ:SGMO) in the 2018 Worldwide CRISPR IP landscape. As the newest and currently most popular gene editing technology in the scientific field, CRISPR has recently received significant investor attention. Indeed, emerging genome engineering technologies have broad applications, ranging from agriculture to cell and gene therapy. The CRISPR market is thus anticipated to reach several billion dollars by the beginning of next decade. Sangamo is primarily known for its strong IP control of the Zinc Finger Nuclease (ZFN) gene editing technology, as developed since the mid 2000s. Consistent with these core intangible assets in the fast-evolving gene editing technology field, Sangamo has been regularly defending the ZFN technology against the emerging CRISPR alternatives since 2013 in their SEC filings as well as investors conferences, such as the JP Morgan Healthcare conference in January However, we observe that Sangamo has also silently positioned IP assets in the CRISPR field. The IPStudies patent analytics data comprise more than 6000 published patent applications derived from 2500 patent families, as well as 70 publicly announced licensing deals in the field of the emerging CRISPR technology applied to genome engineering. These IP assets have been regularly searched, reviewed and categorized along different biotechnology scientific axes by PhD experts according to the IPStudies methodology since As of 2018, Sangamo is listed as part of the Top10 patent applicants in the CRISPR IP landscape. This report reviews the positioning of Sangamo in the CRISPR IP landscape by confronting the IPStudies patent analytics data with publicly available information such as business, scientific and technical communication and documentation about the company and its field. For fundamental analysts, this report enables a more precise qualification of the IP positioning of the company in its competitive landscape and the evaluation of its potential for IP-backed competitive risk mitigation in technologically complex emerging genome editing markets. The report shows in particular: Ø How reactive the Sangamo defense has been against the emergence of CRISPR substitution technologies after the CRISPR-Cas9 tool discovery in Ø How Sangamo adapted its IP strategy to the corporate strategic move towards focusing on therapeutic applications. Ø The scope of CRISPR specific intangible assets designed by Sangamo R&D. Ø A competition benchmarking highlighting Sangamo s technical positioning in the fast developing industrial CRISPR IP landscape. Companies quoted in this benchmark include Cellectis (EPA: ALCLS), CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine ( Editas NASDAQ:EDIT), Intellia Therapeutics ( Intellia NASDQ:NTLA), Caribou Sciences ( Caribou ), Precision Biosciences, Agenovir, and DuPont (NYSE:DD-B). 2

3 3 Backgrounder The technology analyses from IPStudies Sàrl (IPStudies) are based on independent research by IPStudies PhD analysts solely from information sources available to the general public, e.g. company reports, product brochures, investor presentations, websites, patent office databases as well as technology and scientific publications databases. In particular, IP- Studies is not under any contractual relationship with the company analyzed and has no direct or indirect financial interest in it. IPStudies processes the information harvested and formulates its technology evaluation in accordance with its analysis methodology and guidelines. Despite multiple verifications, the information provided cannot be guaranteed accurate. IPStudies concentrates on providing and promoting awareness on advanced technology and intellectual property assets information to the general public. The information contained herein is the opinion of IPStudies and is intended for informational purpose only. The graphical information provided throughout this report is primarily extracted from the January 2018 IPStudies CRISPR patent landscape. For more information on IPStudies CRISPR patent monitoring services please check Any company, product and brand names mentioned herein are trademarks, registered trademarks and/or service marks of their respective owners.

4 EXECUTIVE SUMMARY 2 COMPANY PROFILE MARKET DATA 7 TERRITORIES 8 FINANCIAL ASSETS 8 TECHNOLOGY ASSETS 9 Genome Editing Platform and Applications 10 Gene Regulation Platform 11 PRODUCT PIPELINE AND STRATEGY 11 OVERALL PATENT PORTFOLIO AND COLLABORATIONS 12 OVERALL LICENSING DEALS 13 IP ASSETS IN THE CRISPR PATENT LANDSCAPE 16 CRISPR PATENT PORTFOLIO 16 Claim coverage 16 Research collaborations 17 Country coverage 18 A timely IP response to the CRISPR technology development 18 CRISPR dedicated patent assets 20 COMPETITIVE POSITION IN THE CRISPR PATENT LANDSCAPE 22 CRISPR GENOME EDITING APPLICATIONS 22 CRISPR GENE THERAPY APPLICATIONS 29 CRISPR CELL MODIFICATION APPLICATIONS 34 GENE REGULATION 39 CONCLUSIONS 41 DEFINITIONS 42 4 ABOUT THE ANALYSTS 47

5 5 Figure 1: IP collaborations in the overall patent portfolio Figure 2: IP Assets in the CRISPR Landscape filed by or in collaboration with industrial applicants Figure 3: Comparison of the development of IP assets left: overall portfolio; right: CRISPR related portfolio Figure 4: Claim coverage of Sangamo's assets in the CRISPR Landscape - Applications Figure 5: IP collaborations in the CRISPR patent portfolio Figure 6: Countries in which Sangamo has filed for protection of CRISPR-related IP Figure 7: Filing history of Sangamo CRISPR patent assets Figure 8: Temporal distribution of CRISPR assets claim coverage - Applications Figure 9: Temporal distribution of CRISPR assets claim coverage - Components Figure 10: Temporal distribution of CRISPR assets claim coverage Chimeric proteins Figure 11: Genome editing IP assets in the CRISPR landscape - industrial applicants Figure 12: Sangamo CRISPR gene editing IP sassets - application filings over time Figure 13: Cellectis CRISPR gene editing IP assets - application filings over time Figure 14: DuPont CRISPR gene editing IP assets - application filings over time Figure 15: Editas CRISPR gene editing IP assets - application filings over time Figure 16: Sangamo CRISPR gene editing IP assets evolution of CRISPR-Components over time Figure 17: Editas CRISPR gene editing IP assets evolution of CRISPR-Components over time Figure 18: CRISPR Therapeutics CRISPR gene editing IP assets evolution of CRISPR-Components over time Figure 19: Caribou Sciences CRISPR gene editing IP assets evolution of CRISPR-Components over time Figure 20: DuPont CRISPR gene editing IP assets evolution of CRISPR-Components over time Figure 21: Cellectis CRISPR gene editing IP assets evolution of CRISPR-Components over time Figure 22: Precision Biosciences CRISPR gene editing IP assets CRISPR-Components Figure 23: Sangamo CRISPR gene editing assets - Chimeric proteins Figure 24: DuPont CRISPR gene editing IP assets - Chimeric proteins Figure 25: Editas CRISPR gene editing IP assets - Chimeric proteins Figure 26: Cellectis CRISPR gene editing IP assets - Chimeric proteins Figure 27: CRISPR Therapeutics gene editing IP assets - Chimeric proteins Figure 28: Caribou Biosciences gene editing IP assets - Chimeric proteins Figure 29: Precision Biosciences gene editing IP assets - Chimeric proteins Figure 30: Therapeutic-Diagnostic IP assets in the CRISPR landscape - industrial applicants Figure 31: Sangamo therapeutics-diagnostics CRISPR IP assets - application filings over time Figure 32: Editas therapeutics-diagnostics CRISPR IP assets - application filings over time Figure 33: Editas therapeutics-diagnostics CRISPR IP assets - CRISPR-Components Figure 34: Sangamo therapeutics-diagnostics CRISPR IP assets - CRISPR-Components Figure 35: Agenovir therapeutics-diagnostics CRISPR IP assets - CRISPR-Components Figure 36: CRISPR Therapeutics therapeutics-diagnostics CRISPR assets - CRISPR-Components Figure 37: Sangamo therapeutics-diagnostics CRISPR IP assets - Chimeric proteins Figure 38: Editas therapeutics-diagnostics CRISPR IP assets - Chimeric proteins Figure 39: Agenovir therapeutics-diagnostics CRISPR assets - Chimeric proteins Figure 40: Cellectis therapeutics-diagnostics CRISPR IP assets - Chimeric proteins Figure 41 CRISPR Therapeutics therapeutics-diagnostics CRISPR IP assets - Chimeric proteins Figure 42: Cell modification IP Assets in the CRISPR Landscape - industrial applicants Figure 43: Sangamo cell modification CRISPR IP assets - application filings over time Figure 44: Cellectis cell modification CRISPR IP assets - application filings over time Figure 45: DuPont cell modification CRISPR IP assets - application filings over time Figure 46: Editas cell modification CRISPR IP assets - application filings over time Figure 47: Sangamo cell modification CRISPR IP assets - Components Figure 48: DuPont cell modification CRISPR IP assets - Components Figure 49: Editas cell modification CRISPR IP assets - Components Figure 50: Cellectis cell modification CRISPR IP assets - Components Figure 51: Sangamo cell modification CRISPR IP assets - Chimeric proteins Figure 52: DuPont cell modification CRISPR IP assets - Chimeric proteins Figure 53: Editas cell modification CRISPR IP assets - Chimeric proteins Figure 54: Transcriptional-epigenetic regulation IP Assets in the CRISPR Landscape - industrial applicants... 39

6 Figure 55: Sangamo transcriptional-epigenetic regulation CRISPR IP assets Chimeric proteins Figure 56: DuPont transcriptional-epigenetic regulation CRISPR IP assets Chimeric proteins Figure 57: Editas transcriptional-epigenetic regulation CRISPR IP assets Chimeric proteins

7 About the analysts 47 Dr. Fabien Palazzoli holds a PhD in Life Sciences (2011) and a double MsC in Biotechnology and Law (2007) from the University of Tours in France. From 2007 to 2013, he has worked as contract officer, IP analyst and account manager in various technology transfer and valuation units for France s largest public research organization CNRS, where he developed his scientific expertise in genome engineering, gene and cell therapies, and bioproduction. Dr. Palazzoli joined IPStudies in 2013 to develop its patent analytics offering to biotech ventures in Europe. Since 2014, he has been developing the first worldwide independent CRISPR patent landscape and patent monitoring services. Dr. Laura Buffard holds a PhD in Astrophysics from the University of North Carolina at Chapel Hill (1995) and completed an Executive Program in Corporate Strategy from MIT Sloan School of Management (2008). Prior to developing her strategy consultancy services in 2017, she held senior innovation, product and technology management positions in industries connecting the digital and physical worlds. Over the past decade, Dr. Laura Buffard has assessed dozens of technology companies and portfolios for competitive intelligence, benchmarking, partnership, due diligence and corporate venturing. From 2011 to 2016 Dr. Laura Buffard managed the intellectual property portfolio of the GSS Division of SICPA in Switzerland. Dr. Corinne Le Buhan holds a postgraduate degree in Economics from the University of Strasbourg, specialized in innovation and management of intellectual property (2008), a PhD in communication systems from EPFL in Switzerland (1998) and an MsC in engineering from INSA in France (1994). Prior to funding IPStudies in 2010, Corinne Le Buhan held a number of R&D and IP management positions for 15 years in France and Switzerland. Corinne Le Buhan has setup the IP strategy and developed the patent portfolio for several high-tech companies since 2007 with a strong focus on IP valuation for the US markets. She was appointed as expert for the European Commission on innovation for SMEs from 2013 to She is a member of the International Licensing Executive Society and currently sits at the board of CHPIUG, the Swiss Patent Information User Group.